Comparison of Gilenya with Avonex in relapsing-remitting MS
Posted: Thu May 19, 2011 2:32 am
Summary
Background
In a 12-month phase 3 study in patients with relapsing-remitting multiple sclerosis (RRMS), TRANSFORMS, fingolimod showed greater efficacy on relapse rates and MRI outcomes compared with interferon beta-1a. We had two aims in our extension: to compare year 2 with year 1 in the switched patients to assess the effect of a change from interferon beta-1a to fingolimod, and to compare over 24 months the treatment groups as originally randomised to assess the effect of delaying the start of treatment with fingolimod.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309